A detailed history of Personal Cfo Solutions, LLC transactions in Incyte Corp stock. As of the latest transaction made, Personal Cfo Solutions, LLC holds 7,535 shares of INCY stock, worth $558,795. This represents 0.07% of its overall portfolio holdings.

Number of Shares
7,535
Previous 7,529 0.08%
Holding current value
$558,795
Previous $456,000 9.21%
% of portfolio
0.07%
Previous 0.07%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$57.33 - $68.61 $343 - $411
6 Added 0.08%
7,535 $498,000
Q2 2024

Aug 09, 2024

SELL
$51.18 - $63.75 $2,303 - $2,868
-45 Reduced 0.59%
7,529 $456,000
Q1 2024

May 13, 2024

BUY
$56.55 - $66.59 $565 - $665
10 Added 0.13%
7,574 $431,000
Q4 2023

Feb 13, 2024

SELL
$52.16 - $64.19 $4,642 - $5,712
-89 Reduced 1.16%
7,564 $474,000
Q3 2023

Nov 13, 2023

BUY
$57.77 - $65.93 $3,177 - $3,626
55 Added 0.72%
7,653 $442,000
Q2 2023

Aug 10, 2023

SELL
$60.95 - $75.51 $1,706 - $2,114
-28 Reduced 0.37%
7,598 $472,000
Q1 2023

May 09, 2023

BUY
$70.23 - $86.01 $2,317 - $2,838
33 Added 0.43%
7,626 $551,000
Q4 2022

Feb 14, 2023

BUY
$67.18 - $84.11 $201 - $252
3 Added 0.04%
7,593 $609,000
Q3 2022

Nov 01, 2022

SELL
$66.18 - $82.86 $264 - $331
-4 Reduced 0.05%
7,590 $506,000
Q2 2022

Aug 05, 2022

SELL
$66.18 - $83.18 $132 - $166
-2 Reduced 0.03%
7,594 $577,000
Q1 2022

May 02, 2022

BUY
$66.02 - $79.71 $1,056 - $1,275
16 Added 0.21%
7,596 $603,000
Q4 2021

Feb 11, 2022

BUY
$63.34 - $74.11 $2,280 - $2,667
36 Added 0.48%
7,580 $556,000
Q3 2021

Nov 18, 2021

BUY
$68.67 - $84.02 $518,046 - $633,846
7,544 New
7,544 $519,000
Q1 2020

Apr 30, 2020

SELL
$63.18 - $85.97 $473,850 - $644,775
-7,500 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$72.82 - $86.52 $546,150 - $648,900
7,500 New
7,500 $557,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.5B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Personal Cfo Solutions, LLC Portfolio

Follow Personal Cfo Solutions, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Personal Cfo Solutions, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Personal Cfo Solutions, LLC with notifications on news.